Amicus Therapeutics: Why Analysts Are Bullish on FOLD Stock

Analysts Needham ($14 PT) & Morgan Stanley ($12 PT) are bullish on Amicus. Its DMX-200 drug for FSGS is de-risked by FDA changes, has huge sales potential ($1.5B+), and isn't yet priced into the stock. Both firms issued "Buy" ratings!